Beneficial effects of empagliflozin on hematocrit levels in a patient with severe anemia.
Jan BudzianowskiJanusz RzeźniczakJarosław HiczkiewiczDominika KasprzakAnna Winnicka-ZielińskaBogdan MusielakKonrad PieszkoPaweł BurchardtPublished in: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences (2021)
Eventually, only the introduction of empagliflozin successfully increased the values of hemoglobin and hematocrit. Therefore, it transpires that SGLT2 enhances erythropoietin (EPO) secretion which subsequently raises hematocrit levels in patients with severe anemia.